BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amgen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Amgen's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06430866-2085@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Abp 234: Phase 3 readout est. (NCT06430866)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pharmac
 okinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)\nEstima
 ted primary completion: 14 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abp-234#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06430866
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706817-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06706817)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyposis Initiating Treatment With Tezepelumab\nEstimated primar
 y completion: 13 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06706817
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 39)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 
 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated primary 
 completion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06858839
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858878-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 78)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With
  Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated pr
 imary completion: 21 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06858878
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549258-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT05549258)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study of Inebilizumab in Pediat
 ric Subjects With Neuromyelitis Optica Spectrum Disorder\nEstimated primar
 y completion: 13 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05549258
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700343-7468@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:ABP 692: Phase 3 readout est. (NCT06700343)
DESCRIPTION:ABP 692\, phase 3\, Multiple Sclerosis.\nStudy: Comparison Betw
 een ABP 692 and Ocrevus® (Ocrelizumab)\nEstimated primary completion: 19 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abp-692#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06700
 343
URL:https://assetmemo.bio/drug/abp-692#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987695-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT069876
 95)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in J
 apan Who Have Obesity Disease\nEstimated primary completion: 27 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06987695
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871409-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078714
 09)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Home Self-administration of Maridebart Cafraglutide With Autoinjector in 
 Adults Living With Obesity or Overweight\nEstimated primary completion: 16
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maridebar
 t-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07871409
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473779-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06473779)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Open-label S
 tudy to Assess Reduction of Background Asthma Medication While Sustaining 
 Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yr
 s With Severe Asthma.\nEstimated primary completion: 25 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06473779
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969329-878@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03969329)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Secondary Hyperparathyroid
 ism.\nStudy: A Phase 3 Study of Etelcalcetide in Children With Secondary H
 yperparathyroidism Receiving Hemodialysis\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etelcalc
 etide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03969329
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920356-1987@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sotorasib: Phase 3 readout est. (NCT05920356)
DESCRIPTION:Sotorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab 
 Platinum Doublet Combination as a Front-Line Therapy in Participants With 
 Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers 
 (CodeBreaK 202)\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05920356
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321601-955@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270718
DTEND;VALUE=DATE:20270719
SUMMARY:Tavneos (Avacopan): Phase 3 readout est. (NCT06321601)
DESCRIPTION:Tavneos (Avacopan)\, phase 3.\nStudy: Study to Evaluate Avacopa
 n in Combination With a Rituximab or Cyclophosphamide-containing Regimen\,
  in Children From 6 Years to < 18 Years of Age With AAV.\nEstimated primar
 y completion: 18 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06321601
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225686-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072256
 86)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstruc
 tive Sleep Apnea on Positive Airway Pressure Therapy\nEstimated primary co
 mpletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07225686
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441252-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:MariTide (maridebart cafraglutide): Phase 2 readout est. (NCT074412
 52)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 2\, Obesity.\nStudy:
  A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adu
 lts Living With Elevated Liver Fat and Obesity or Overweight\nEstimated pr
 imary completion: 25 August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07441252
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226765-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072267
 65)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3.\nStudy: Maridebar
 t Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep
  Apnea Not on Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07226765
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778316-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07778316)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Phase 3 
 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer A
 fter Platinum Based First-line Chemotherapy (ES-SCLC)\nEstimated primary c
 ompletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07778316
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04521231-5633@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT04521231)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab Administration in Participants With
  R/R and MRD+ B-ALL\nEstimated primary completion: 24 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04521231
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684144-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076841
 44)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-2-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684144
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684235-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076842
 35)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-1-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684235
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05060016-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT05060016)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05060016
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575399-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT075753
 99)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy\, Safety and Tolerability of Switching From Glucagon-like Peptid
 e-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With 
 Obesity or Overweight (MARITIME-SWITCH)\nEstimated primary completion: 3 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/marideba
 rt-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07575399
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-2085@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Abp 234: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Ad
 vanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abp-234#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363642-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07363642)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: Phase 3b Stu
 dy in Patients With Severe Asthma Treated With Tezepelumab\nEstimated prim
 ary completion: 7 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tezepelumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363642
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520162-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT07520162)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3.\nStudy: A Study to Investigat
 e NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Tr
 eatment With Tezepelumab\nEstimated primary completion: 1 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tezepelumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07520162
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04804553-95@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04804553)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: Ap
 remilast Pediatric Study in Children With Active Juvenile Psoriatic Arthri
 tis\nEstimated primary completion: 21 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04804553
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581303-1039@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olpasiran: Phase 3 readout est. (NCT05581303)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion (OCEAN(a)) - Outcomes Trial\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olpasiran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05581303
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023589-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06023589)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Asthma.\nStudy: A Study to I
 nvestigate the Efficacy and Safety of Tezepelumab Compared With Placebo in
  Children 5 to < 12 Years Old With Severe Asthma\nEstimated primary comple
 tion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 zepelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06023589
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293260-1039@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07293260)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion - Coronary Computed Tomography Angiography Trial\nEstimated primary co
 mpletion: 15 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/olpasiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07293260
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037433-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 33)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcom
 es in Participants With Atherosclerotic Cardiovascular Disease and Overwei
 ght or Obesity\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07037433
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037459-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 59)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced
  Ejection Fraction and Obesity\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07037459
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172919-1987@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07172919)
DESCRIPTION:Sotorasib\, phase 2.\nStudy: A Rollover Study Evaluating Sotora
 sib With or Without Panitumumab in Participants With KRAS p.G12C Mutation\
 nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07172919
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Inebilizumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866066-143@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280906
DTEND;VALUE=DATE:20280907
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078660
 66)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Type 2 Diabetes.
 \nStudy: Maridebart Cafraglutide Versus Semaglutide in Participants With T
 ype 2 Diabetes\nEstimated primary completion: 6 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07866066
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252649-1987@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Sotorasib: Phase 3 readout est. (NCT06252649)
DESCRIPTION:Sotorasib\, phase 3\, Colorectal Cancer.\nStudy: Study of Sotor
 asib\, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-
 awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer Wi
 th KRAS p.G12C Mutation\nEstimated primary completion: 25 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06252649
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005128-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07005128)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 Comparing Tarlatamab\, Durvalumab\, Carboplatin\, and Etoposide Versus Dur
 valumab\, Carboplatin\, and Etoposide in First-line Extensive Stage Small-
 Cell Lung Cancer (ES-SCLC)\nEstimated primary completion: 4 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07005128
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03633708-878@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03633708)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Chronic Kidney Disease.\nS
 tudy: A Trial of Etelcalcetide in Pediatric Participants With Secondary Hy
 perparathyroidism and Chronic Kidney Disease on Hemodialysis\nEstimated pr
 imary completion: 31 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/etelcalcetide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03633708
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878261-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06878261)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 7)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06878261
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883305-1507@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290313
DTEND;VALUE=DATE:20290314
SUMMARY:Tezspire (tezepelumab): Phase 3 readout est. (NCT06883305)
DESCRIPTION:Tezspire (tezepelumab)\, phase 3\, Chronic Obstructive Pulmonar
 y Disease.\nStudy: A Study to Investigate the Efficacy and Safety of Tezep
 elumab in Adult Participants With Moderate to Very Severe COPD (D5241C0000
 6)\nEstimated primary completion: 13 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tezepelumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06883305
URL:https://assetmemo.bio/drug/tezepelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745323-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290810
DTEND;VALUE=DATE:20290811
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06745323)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2\, Open-label\, Randomized\, Multicenter Study of Tarlatamab Dosing Regim
 ens in Subjects With SCLC\nEstimated primary completion: 10 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06745323
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04994717-5633@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04994717)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy V
 ersus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed 
 Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia\nEstim
 ated primary completion: 7 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04994717
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04528082-95@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20300207
DTEND;VALUE=DATE:20300208
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04528082)
DESCRIPTION:Otezla (apremilast)\, phase 3.\nStudy: Apremilast Pediatric Stu
 dy in Children With Active Oral Ulcers Associated With Behçet's Disease\n
 Estimated primary completion: 7 February 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04528082
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987539-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06987539)
DESCRIPTION:Inebilizumab\, phase 2\, Generalized Myasthenia Gravis.\nStudy:
  A Study to Evaluate the Pharmacokinetics\, Pharmacodynamics\, Safety and 
 Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravi
 s (gMG)\nEstimated primary completion: 13 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06987539
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06211036-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06211036)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Co
 mparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Ex
 tensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum\, Etopos
 ide and Durvalumab\nEstimated primary completion: 2 April 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06211036
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06117774-2753@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20300420
DTEND;VALUE=DATE:20300421
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06117774)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Ev
 aluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lu
 ng Cancer (LS-SCLC)\nEstimated primary completion: 20 April 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06117774
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134088-5633@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07134088)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B
 -Cell Precursor Acute Lymphoblastic Leukemia\nEstimated primary completion
 : 6 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07134088
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222553-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20310610
DTEND;VALUE=DATE:20310611
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT07222553)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study to Evaluate the Pharmacok
 inetics\, Pharmacodynamics\, Safety\, and Tolerability of Inebilizumab in 
 Pediatric Participants With IgG4-RD\nEstimated primary completion: 10 June
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222
 553
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598825-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07598825)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Trial of Inebilizumab in Part
 icipants With Autoimmune Hepatitis\nEstimated primary completion: 30 July 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075988
 25
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851220-5632@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20310927
DTEND;VALUE=DATE:20310928
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07851220)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Phase 3 Study of Inebilizumab
  in Participants With Primary Membranous Nephropathy\nEstimated primary co
 mpletion: 27 September 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07851220
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136012-1039@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20311020
DTEND;VALUE=DATE:20311021
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07136012)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And L
 ipoprotein(a) Reduction to Prevent First Major Cardiovascular Events\nEsti
 mated primary completion: 20 October 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olpasiran#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07136012
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223190-5633@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07223190)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly D
 iagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia\nEstim
 ated primary completion: 30 December 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07223190
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05767047-95@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20360317
DTEND;VALUE=DATE:20360318
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT05767047)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: A 
 Study of Apremilast in Children With Oral Ulcers Associated With Behçet's
  Disease or Juvenile Psoriatic Arthritis\nEstimated primary completion: 17
  March 2036. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apremila
 st#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5767047
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
